近日，国内医美服务平台新氧推出"奇迹童颜3.0-塑缇妍"童颜针（与西宏生物合作获得的定制版产品，为水光型号）， 其2999元的定价被业 内直接冠以"史上最低价"之称，直接打破了此前万元级的市场均价常态。 相较更早进入市场，大众熟知度更高的玻尿酸（透明质酸钠），首款童颜针于2021年才在国内获批， 并自此打 开了该产品在医美行业的巨 大想象力。 这款曾因定位高端、被戏称为"贵妇快乐水"的医美产品， 如今随着越来越多品牌玩家的入局，其过去相对稳固的市场竞争体系或将迎来新 一轮重构。 而"平价童颜针"的推出，也意味着童颜针市场已来到"价格战前夜"的关键节点 。 九款产品贴身肉搏，市场进入"混战"阶段 资料显示，童颜针属于"医美再生注射剂"，这类注射剂是一种以生物刺激性材料为主要成分，可注射到真皮层、皮下组织、筋膜层和肌肉层 中，通过刺激人体自身胶原蛋白的再生，从而起到重塑紧致、美容抗衰作用的皮肤填充剂。 目前全球范围内已上市的医美再生注射剂主要产品的微球粒子主要分为PLLA、PDLLA、PCL和羟基磷灰石四大类，其中，以PLLA、 PDLLA为核心成分的被称为"童颜针"。 据头豹研究院行业报告数据，到2027年，中 ...

Core Viewpoint - The article discusses the ongoing price war in the aesthetic medicine market, particularly focusing on the "童颜针" (youthful needle) products, highlighting the conflict between upstream material suppliers and downstream clinics, with New Oxygen's pricing strategy causing significant market disruption [2][4][39]. Group 1: Market Dynamics - New Oxygen's self-operated clinic is selling the "艾维岚" (Aivilan) product at 5,999 yuan, which is one-third of the market price of 18,000 yuan, leading to dissatisfaction from the brand owner, Changchun Shengboma [2][12]. - The price war is intensifying as more competitors enter the market, with at least seven "童颜针" products now approved for sale in China, compared to only two in 2021 [32][36]. - The market for "童颜针" is projected to grow from 1.488 billion USD in 2024 to 2.082 billion USD by 2033, indicating significant potential for growth despite current pricing pressures [29]. Group 2: Company Strategies - New Oxygen has established a strategic partnership with Oriental Yanmei, securing exclusive rights to commercialize several upcoming products, including the XH301 "童颜针" [6][21]. - Oriental Yanmei's XH301 is expected to complete its domestic listing review in the second half of the year, with the company currently facing a projected revenue of only 0.13 million yuan for 2024 and a loss of 0.64 million yuan [9][19]. - The company plans to adopt an agency sales model rather than direct sales, which is seen as a safer approach given its current financial situation [20][25]. Group 3: Product Development - The XH301 product, which utilizes a combination of PLLA and CMC, is designed to stimulate collagen regeneration and improve skin tightness, with a reported effectiveness rate of 95.5% in correcting severe wrinkles [18]. - The competitive landscape is challenging for XH301, as it faces pricing pressures from existing products and the potential for lower-priced alternatives to emerge [38][44]. - Oriental Yanmei is also exploring overseas markets for its products, which may provide additional growth opportunities amid domestic competition [48][50].